Finance

Beta
Lists
GERN:NASDAQ
Geron Corp
$1.17
-3.31%
(-0.040) 1D
$1.18
+0.85% (+0.0100)
After hours
Closed: Jun 5, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GERN...
Open
$1.21
High
$1.21
Low
$1.16
Mkt. cap
750.58M
Avg. vol.
13.30M
Volume
9.60M
52-wk high
$2.01
52-wk low
$1.04
EPS
-$0.10
Beta
0.60
Shares outstanding
641.52M
No. of employees
258
Open
$1.21
High
$1.21
Low
$1.16
Mkt. cap
750.58M
Avg. vol.
13.30M
Volume
9.60M
52-wk high
$2.01
52-wk low
$1.04
EPS
-$0.10
Beta
0.60
Shares outstanding
641.52M
No. of employees
258
Analyst outlook
Analyst Ratings
Based on 4 analysts giving stock ratings to GERN in the past 3 months
Strong Buy
Buy
3
Hold
1
Sell
0
12 month forecast
Based on 4 Wall Street analysts offering 12 month price targets for GERN in the last 3 months.
Highest
Current $1.17
$5.00 (+327.35%)
Average
$4.00 (+241.88%)
Lowest
$3.00 (+156.41%)
News stories
From sources across the web
Profile
Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase. Wikipedia
About Geron Corp
CEOJohn A Scarlett
Employees258
Founded1990
HeadquartersMenlo Park, California, United States
SectorBiotechnology
Websitegeron.com
Last report
May 6, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.00 / -$0.02
+75.50%beat
Revenue / Est. (USD)
51.84M / 50.59M
+2.47%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
49.04M
47.23M
48.02M
51.84M
Cost of goods sold
22.93M
22.11M
14.86M
16.65M
Cost of revenue
22.93M
22.11M
14.86M
16.65M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
38.56M
39.00M
41.67M
35.42M
Operating expense
38.56M
39.00M
41.67M
35.42M
Total operating expenses
61.49M
61.11M
56.52M
52.07M
Operating income
-12.45M
-13.89M
-8.51M
-236.00K
Other non operating income
-61.00K
-161.00K
-70.00K
-74.00K
EBT including unusual items
-16.38M
-18.43M
-28.86M
-3.64M
EBT excluding unusual items
-16.38M
-18.43M
-11.83M
-4.04M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-16.38M
-18.43M
-28.86M
-3.64M
Net profit margin
-33.39%
-39.02%
-60.11%
-7.03%
Earnings per share
-0.02
-0.03
-0.02
-0.00
Interest and investment income
4.66M
4.26M
4.04M
3.42M
Interest expense
-8.52M
-8.64M
-7.30M
-7.15M
Net interest expenses
-3.86M
-4.38M
-3.25M
-3.73M
Depreciation and amortization charges
-
-
-
-
EBITDA
-12.33M
-13.76M
-8.42M
-102.00K
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer